SciELO - Scientific Electronic Library Online

 
vol.14 número5Estado actual de las unidades de dolor agudo en AndalucíaParche de lidocaína al 5% para el tratamiento del SDRC de extremidad superior por bloqueo transcutáneo del plexo braquial: Caso Clínico índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista de la Sociedad Española del Dolor

versión impresa ISSN 1134-8046

Resumen

CALDERON, E. et al. Oxycodone in non-oncological chronic pain: Effects on quality of life parameters. Rev. Soc. Esp. Dolor [online]. 2007, vol.14, n.5, pp.346-350. ISSN 1134-8046.

Objectives: To evaluate the effectiveness and safety of controlled reléase oxicodone in mixed pain mixed in patients with non oncológical severe pain, as well as its interference on the pain and quality of life. Material and Methods: Prospective study. 34 patients with mixed pain (nociceptive and neuropáthic). 1 month minimum pain duration. The brief questionnaire for the evaluation of the pain was used (CBD), the interference with functional parameters of quality of life: general activity, mood, walking, work, relationship with other people and sleep. Starting oxicodone controlled reléaselo mg/12 h and rescue analgesia with oxicodone fast reléase 20 mg/day with progressive increase every 15 days until obtaining adapted control of the pain. Acetaminophen 650 mg/6 h was used as associate medication. The patients were evaluated at 30 and 60 days. Results: The average age of our patients was of 69 ± 7 years, the average dose of oxicodone to provide a suitable control of the pain were 37 ± 6 mg to the day. Oxicodone significantly reduce the intensity of severe pain after 30 and 60 days of treatment, and respectively provided a lightening of the pain 48% and 67%. The parameters of sleeping and relationship with the others improved significantly at the end of the study. The most frequent adverse event was constipation (14,7%). Conclusions: Controlled reléase oxicodone 37 mg/day provides a significant reduction in the intensity of severe pain lasting until second month of treatment with an improvement in the of quality of life.

Palabras clave : Opiate; oxicodone; nononcológical chronic pain; brief questionnaire pain; quality of life.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons